The amplification of putative oncogenes is a common finding within the genome of various cancer types. Identification and further targeting of specific junction sites within the sequence of genomic amplicons (amplicon fusion sites, AFS) by PCR (AFS-PCR) is suitable for quantification of minimal residual disease (MRD). This approach has recently been developed and described for MYCN amplified ne...

UNLABELLED Medical Record Department (MRD) has a vital role in making short and long term plans to improve health system services. The aim of this study was to describe performance improvement indicators of hospital MRD and information technology (IT). COLLECTION OF DATA A search was conducted in various databases, through related keywords in articles, books, and abstracts of conferences from...

Persistence or recurrence of minimal residual disease (MRD) after chemotherapy results in clinical relapse in patients with acute lymphoblastic leukemia (ALL). In a phase 2 trial of B-lineage ALL patients with persistent or relapsed MRD, a T cell-engaging bispecific Ab construct induced an 80% MRD response rate. In the present study, we show that after a median follow-up of 33 months, the hemat...

In adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph ALL), minimal residual disease (MRD) after stem cell transplantation (SCT) is associated with a relapse probability exceeding 90%. Starting imatinib in the setting of MRD may decrease this high relapse rate. In this prospective multicenter study, 27 Ph ALL patients received imatinib upon detection of MRD after SCT. Bcr-a...

Achieving deep levels of remission is one of the prerequisites to reach long-term survival in solid tumors and hematologic malignancies, and this has also been proved in newly diagnosed multiple myeloma (MM) patients, particularly in the era of novel agents. Accordingly, both the Spanish and UK groups have shown the prognostic value and clinical relevance of minimal residual disease (MRD) monit...

AIM Detection of the possible impact of surgical management on the occurrence of minimal residual disease (MRD) in patients with colorectal carcinoma (CRC) in bone marrow samples, portal and peripheral blood samples. Comparison of MRD prevalence in patients with laparoscopic resection of CRC and those with open colorectal resection. Assessment of the potential impact of MRD on the relapse of th...

Purpose: High-throughput sequencing (HTS) of immunoglobulin heavy-chain genes (IGH) in unselected clinical samples for minimal residual disease (MRD) in B lymphoblastic leukemia (B-ALL) has not been tested. As current MRD-detecting methods such as flow cytometry or patient-specific qPCR are complex or difficult to standardize in the clinical laboratory, sequencing may enhance clinical

Acute promyelocytic leukemia (APL) is a molecularly well-defined disease, characterized by a specific chromosomal translocation; the improvement in biologic and clinical knowledge and subsequent introduction of molecularly targeted therapies have transformed the management of APL, with survival rates now exceeding 80%. Minimal residual disease (MRD) assessment in APL is the most important tool ...

BACKGROUND AND OBJECTIVES The molecular analysis of minimal residual disease (MRD) may provide information on the risk of recurrence in patients with acute lymphoblastic leukemia (ALL). The aim of this study was to correlate the kinetics of MRD clearance after allogeneic transplantation with the clinical outcome of adults with ALL. DESIGN AND METHODS MRD was evaluated by real-time quantitativ...

Proofs of Data Possession (PoDP) scheme is essential to data outsourcing. It provides an efficient audit to convince a client that his/her file is available at the storage server, ready for retrieval when needed. An updated version of PoDP is Proofs of Retrievability (PoR), which proves the client’s file can be recovered by interactions with the storage server. We propose a PoDP/PoR scheme base...